reports
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements ...
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma’s unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy t...
Barnwell Announces Third Adjournment of 2025 Annual Meeting Due to Ned...
Barnwell Announces Third Adjournment of 2025 Annual Meeting Due to Ned Sherwood’s Continued Refusal to Submit Votes Solicited from Shareholders HONOLULU, June 18, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today announced that its 2025 Annual Meeting of Shareholders, which reconvened yesterday, has been adjourned to Wednesday, September 3, 2025. Shareholders of record at the close of business on July 21, 2025 are eligible to vote at the adjourned 2025 Annual Meeting. Shareholders are encouraged to vote on the WHITE proxy card FOR...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
LINC LINCOLN EDUCATIONAL SERVICES
IMAX IMAX CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
PATK PATRICK INDUSTRIES INC.
MEG. MEG ENERGY CORP.
HRTG HERITAGE INSURANCE HOLDINGS INC.
ELF E.L.F. BEAUTY INC.
PAYS PAYSIGN INC
RPRX ROYALTY PHARMA PLC CLASS A
IMTX IMMATICS N V (A)
CVAC CUREVAC NV
IHS IHS HLDG LTD
SGHC SUPER GROUP (SGHC) LIMITED
CMPO COMPOSECURE INC
FTREV FORTREA HOLDINGS INC.
SGMT SAGIMET BIOSCIENCES INC
PC PREMIUM CATERING HOLDINGS LIMITED
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Heal...
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funde...
Royalty Pharma Completes the Acquisition of Its External Manager
Royalty Pharma Completes the Acquisition of Its External Manager NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma’s shareholders, with 99.9% of votes cast in favor of the transaction. “The completion of the internalization marks an exciting new chapter for Royalty Pharma,” said Pablo Legorreta, founder and Chief Executive Officer. “It reinforces our commitment to transpa...
Barnwell Industries, Inc. Reports Results for its Second Quarter Ended...
Barnwell Industries, Inc. Reports Results for its Second Quarter Ended March 31, 2025 HONOLULU, May 15, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) today reported financial results for its second quarter ended March 31, 2025. For the quarter, the Company had revenue from continuing operations of $3,569,000 and a net loss from continuing operations of $1,538,000 or $0.15 per share. In the prior year quarter ended March 31, 2024, the Company reported quarterly revenue from continuing operations of $4,678,000 and a net loss from continuing operations of $1,306,000...
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET / 2:20 p.m. PTRBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET The webcasts will be accessible from Royalty Pharma’s “Events” page at . Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma Fou...
Royalty Pharma Announces Shareholder Approval of its External Manager ...
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsRoyalty Pharma’s diversified royalty portfolio to be combined with intellectual capital ...
Royalty Pharma Reports First Quarter 2025 Results
Royalty Pharma Reports First Quarter 2025 Results Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Recei...
Moody's Ratings upgrades Royalty Pharma's rating to Baa2; outlook is s...
Moody's Ratings (Moody's) upgraded the senior unsecured notes of Royalty Pharma plc ("Royalty Pharma") to Baa2 from Baa3. At the same time, we revised the outlook to stable from positive. The upgrade reflects our expectation that Royalty Pharma will continue to generate strong earnings growth from...
Royalty Pharma Declares Second Quarter 2025 Dividend
Royalty Pharma Declares Second Quarter 2025 Dividend NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...
Royalty Pharma to Announce First Quarter 2025 Financial Results on May...
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at to obtain conference call information and to view the live webcast. A replay of the conference ca...
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Dir...
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. “I am excited to announce that we are strengthening our Board with...
Royalty Pharma Announces Upcoming Investor Day
Royalty Pharma Announces Upcoming Investor Day NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. Additional details will follow closer t...
Barnwell Industries Corrects Ned Sherwood’s Misleading Claims
Barnwell Industries Corrects Ned Sherwood’s Misleading Claims Alex Kinzler does NOT support Sherwood’s Consent Solicitation Consent Submitted by Alex Kinzler for One Share Required to Commence Consent Solicitation Urges Shareholders to Ignore and Discard any Blue Consent Solicitation Card HONOLULU, March 19, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today corrected the record regarding Ned Sherwood’s highly misleading statements made in connection with his attempt to take over Barnwell without paying a premium to shareho...
Barnwell Industries, Inc. Announces Sale of its Water Drilling Subsidi...
Barnwell Industries, Inc. Announces Sale of its Water Drilling Subsidiary for $1,050,000 Sale Will Streamline Parent Company Operations to Focus on Oil and Natural Gas Business HONOLULU, March 17, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today announced the sale of its wholly owned subsidiary, Water Resources International, Inc. (“Water Resources”), a deep drilling and well pumping specialist in the exploration and development of groundwater resources for government, commercial and private clients in Hawaii, for $1,050,000. Pr...
Moody's Ratings affirms R.R. Donnelley & Sons Company's CFR at B3
Moody's Ratings (Moody's) has affirmed R.R. Donnelley & Sons Company's (RRD) B3 corporate family rating (CFR) and the B3-PD probability of default rating. We have also affirmed the rating on the senior secured notes at B1 and the ratings on the senior unsecured notes and junior lien senior secured n...
Barnwell Industries, Inc. Disqualifies Ned Sherwood’s Board Nominees I...
Barnwell Industries, Inc. Disqualifies Ned Sherwood’s Board Nominees Included in Defective and Insufficient Nomination Notice for 2025 Annual Meeting Sets March 14, 2025, as Record Date for Shareholders to Act by Written Consent in Connection with Sherwood’s Latest Self-Serving Campaign to Take Control of Barnwell Sherwood’s Consent Solicitation is Yet Another Attempt to Steal the Company from Shareholders Without Paying a Premium for Control HONOLULU, March 05, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today announced that the...
Barnwell Industries, Inc. Announces Entering into a Non-Binding Letter...
Barnwell Industries, Inc. Announces Entering into a Non-Binding Letter of Intent for the Sale of its Water Well Drilling Subsidiary HONOLULU, March 05, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today announced that it had entered into a non-binding letter of intent for the sale of Water Resources International, Inc., its water well drilling subsidiary. The Company anticipates that the transaction, for an expected aggregate value of $1,050,000, would close in late March 2025. A portion of the consideration would be paid at the clo...
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Confer...
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharm...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.